The FDA has granted Fast Track Designation to Lundbeck’s investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA).
Alterity Therapeutics Limited (market cap: $40 million), a pharmaceutical company specializing in the development of therapeutic drugs, has secured A$40 million in funding to advance the development ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback